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Cyclin-dependent kinase-5 is widely expressed and
predominantly regulated by the non-cyclin activator p35.
Since we recently showed that expression of p35 in the
kidney is restricted to podocytes, we examined here its
function in mice in which p35 was genetically deleted. The
mice did not exhibit kidney abnormalities during glomerular
development or during adult life. Conditionally immortalized
cultured podocytes, derived from these null mice, did not
have any change in their morphology, differentiation, or
proliferation. However, when these cultured podocytes were
exposed to UV-C irradiation, serum depletion, puromycin
aminonucleoside, or transforming growth factor-b-1, they
showed increased apoptosis compared to those from
wild-type mice. Levels of Bcl-2 were decreased in these null
podocytes but increased after transduction with human p35.
Restoration of p35 or the ectopic expression of Bcl-2 reduced
the susceptibility of p35-null podocytes to apoptosis.
Experimental glomerulonephritis, characterized by podocyte
apoptosis and subsequent crescent formation, was utilized to
test these findings in vivo. Podocyte apoptosis was
significantly increased in diseased p35-null compared with
wild-type mice, accompanied by increased
glomerulosclerosis and decreased renal function. Our study
shows that p35 does not affect glomerulogenesis but
controls podocyte survival following injury, in part, by
regulating Bcl-2 expression.
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Glomerular diseases are a leading cause of chronic and end-
stage kidney failure. The terminally differentiated and highly
specialized glomerular epithelial cell, the podocyte, is a
critical component of the glomerular filtration barrier, and is
required for normal glomerular integrity. A major mechan-
ism underlying the development of glomerulosclerosis and
proteinuria in disease is reduced podocyte number resulting
from apoptosis, detachment, and the inability to adequately
proliferate. Podocyte apoptosis has been reported in diabetic
kidney disease,1 membranous nephropathy,2 HIV-associated
nephropathy, and focal segmental glomerulosclerosis.3,4
Contrary to earlier belief that cell-cycle protein function
was limited to the regulation of proliferation, recent studies
have shown that specific cell-cycle proteins also have
biological roles governing apoptosis.5–8 Among these is
cyclin-dependent kinase (Cdk)-5, which unlike other Cdks,
is not involved in the regulation of cell-cycle progression and
proliferation. Cdk5 modulates cell maturation, differentia-
tion, migration, and apoptosis in various tissues.9–11 Within
the kidney, glomerular expression of Cdk5 is limited to
podocytes. In contrast to other Cdks that are activated by
partner cyclins, published data show that Cdk5 is activated by
non-cyclin proteins p35 or p39.12 p35, but not p39, is
constitutively expressed in podocytes and forms an active
complex with Cdk5.13 However, the role of p35 in podocytes
is poorly understood.
In this study we delineated one function of p35 in
podocytes and glomerular biology by using p35-null mice
and cultured immortalized p35-null podocytes.
RESULTS
Characterization of conditionally immortalized p35-null
podocytes
To generate cultured immortalized podocytes, wild-type and
p35-null mice were crossed with H-2Kb-tsA58 mice
(ImmortoMice; Jackson Laboratory, Bar Harbor, ME,
USA14), and podocytes from the resultant wild-type and
p35-null mice were isolated as previously reported (for
review see reference Shankland et al.15). Quiescence and
differentiation were induced by culturing cells at 37 1C for
13–15 days in the absence of interferon-g. Under these
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conditions, absence of p35 did not affect podocyte prolifera-
tion (data not shown) nor morphology (Figure 1). To assess
the effect of p35 on podocyte differentiation, the expression
of podocyte-specific marker proteins WT-1, nephrin, and
synaptopodin was measured by indirect immunofluorescence
(Figure 1). Both wild-type and p35-null cells showed nuclear
staining for WT-1, characteristic radial distribution of
synaptopodin, as well as cortical localization of nephrin.
Thus, lack of p35 had no effect on podocyte differentiation in
culture as judged by expression of these proteins. This
observation was similar to in vivo results, where p35-null
mice had normal kidney histology when bred under
physiological conditions (see below).
Taken together, these results confirmed that both wild-
type and p35-null podocytes generated for this study were
indeed fully differentiated, quiescent podocytes, and were
thus suitable for the proposed studies. These results also
show that p35 was not essential for normal podocyte
differentiation.
p35-null mice have normal renal function under
physiological conditions in vivo
To test the role of p35 in renal development in vivo, wild-type
Balb/C and p35-null Balb/C mice were used. Renal histology
and function were evaluated in 12-week-old, male, wild-type
and p35-null mice housed under non-stressed conditions.
There were no significant differences in podocyte number or
urinary protein excretion. Likewise, p35-null mice had no
kidney histological abnormalities (by light microscopy) when
bred under physiological (non-stressed) conditions. To assess
podocyte differentiation, the expression of several podocyte-
specific proteins was determined by immunohistochemistry
(Figure 2). Absence of p35 did not affect immunostaining for
WT-1, podocin, nephrin, and synaptopodin. Thus, these
results were similar to that observed in cultured podocytes.
Taken together, p35 alone is not required for normal
glomerular development and differentiation under physiolo-
gical conditions, and its absence does not affect renal
function.
Cultured p35-null podocytes are more susceptible
to apoptosis
To test the hypothesis that p35 governs podocyte survival and
thereby sets a threshold for injury-induced apoptosis, the
following forms of injury were used to induce apoptosis as we
have previously reported:16–18 (i) UV-C initiates both intrinsic
and extrinsic caspase-dependent pathways of apoptosis;19
(ii) puromycin aminonucleoside (PAN) primarily activates
the intrinsic pathway independent of caspase-3 activation;17,20
(iii) Transforming Growth Factor-b-1 (TGFb1) induces
caspase-3-dependent podocyte cell death;18,21 and (iv) serum
starvation causes caspase-3-dependent death.22 The anti-
glomerular antibody causes apoptosis that is associated with
increased cleaved caspase-3 immunostaining.23
Apoptosis was determined by two methods: DNA
condensation measured using Hoechst-33342 and caspase-3
cleavage. In response to each form of injury described above,
the onset of apoptosis occurred significantly earlier in p35-
null podocytes (Po0.05 versus wild-type cells) (Figure 3).
Moreover, with each form of injury, the magnitude of
apoptosis was also increased in p35-null podocytes (Po0.05
versus wild-type cells) (Figure 3a–f). Importantly, increased
apoptosis was confirmed in p35-null podocytes by a second
method, showing caspase-3 cleavage products by Western
blot analysis (Figure 3g). Taken together, these results show
that although the absence of p35 alone is not sufficient to
induce apoptosis, but that p35 is required to prevent
apoptosis induced by four different forms of injury in
cultured podocytes.
Lowering p35 by siRNA in wild-type podocytes increases
apoptosis
A second approach was used to confirm a role for p35 in
enhancing podocyte survival and thus limiting apoptosis by
transfecting wild-type podocytes with small interfering
RNA (siRNA) to p35, to transiently lower p35 levels. Non-
transfected podocytes and podocytes transfected with
scrambled siRNA served as controls. Successful p35 gene
silencing was confirmed by real-time quantitative PCR
(Figure 4a). There was a 68%±19% reduction in p35 mRNA
+/+
×100Bright field
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×200 ×200
×200×200
×200 ×200
×100
p35–/–
Figure 1 |Characterization of conditionally immortalized p35-
null podocytes. Representative images of wild-type (left column)
and p35-null (right column) podocytes at day 14: bright field (a,
b), nephrin (c, d) synaptopodin (e, f), and WT-1 (g, h) staining.
There were no differences in intensity or subcellular localization
between p35-null and wild-type cells.
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levels 48 h post transfection as compared with the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Cells were exposed to UV-C irradiation (25 J/m2)
to induce caspase-dependent apoptosis. Caspase-3 cleavage
was substantially increased after lowering p35 levels with p35
siRNA as compared with that in control siRNA-transfected
wild-type podocytes (Figure 4b). These results confirm that
specific depletion of p35 increases podocyte susceptibility to
apoptosis following injury.
Increasing levels of p35 in p35-null podocytes decreases
apoptosis
To further confirm a role for p35 in podocyte survival, p35
was re-expressed in p35-null podocytes by lentiviral gene
transfer. First, p35 expression was confirmed by Western
blotting. p35-null podocytes transduced with human p35.V5
revealed a strong band at approximately 37 kDa (Figure 4c).
A green fluorescent protein (GFP) construct (28 kDa) served
as control. Restoration of p35 protein in p35-null podocytes
partially decreased UV-C-, and PAN-induced apoptosis
(Hoechst-33342 staining; Figure 4d). Similar results were
obtained by Western blot for caspase-3 cleavage products
following UV-C (data not shown). These results further
confirm a role for p35 in podocyte susceptibility to apoptosis
following injury.
Restoring p35 or Bcl-2 protein expression rescues
p35-null podocytes from apoptosis
To determine how p35 might regulate podocyte apoptosis, we
focused on the pro-survival protein Bcl-2 as our group has
previously shown that changes in Bcl-2 are involved in
podocyte apoptosis.17,18 Figure 5a shows that Bcl-2 expres-
sion is constitutive and abundant in cultured wild-type
podocytes. In contrast, Bcl-2 protein levels were barely
+/+
WT-1
Nephrin
Podocin
Synaptopodin
No 1ο antibody
No 1ο antibody
No 1ο antibody
No 1ο antibody
+/+p35–/–
Figure 2 |p35-null mice exhibit normal glomerular and podocyte differentiation. Representative images of wild-type (left column)
and p35-null (middle column) glomeruli, and immunostaining controls showing there were no differences in staining for WT-1 (a, b),
nephrin (d, e), podocin (g, h) or synaptopodin (j, k) between wild-type and p35-null mice. As expected, staining was not detected when the
primary antibody was omitted (c, f, i, l).
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detected in p35-null podocytes. To test the hypothesis that
Bcl-2 protein levels underlie the pro-survival effect of p35,
p35-null podocytes were stably infected with a retroviral
construct (cMMP-IRES-GFP) containing human Bcl-2. As
overexpression of Bcl-2 could potentially override any
apoptotic phenotype, due to its important role in governing
mitochondrial permeability and release of pro-apoptotic
factors, the levels of ectopically expressed human Bcl-2 in
p35-null podocytes were compared with those in wild-type
cells. Ectopic expression of human Bcl-2 normalized Bcl-2
protein to levels comparable to endogenous levels in wild-
type cells (Figure 5a). An empty plasmid served as control.
Cells were then subjected to increasing doses of UV-C and
cleaved caspase-3 was measured by Western blot analysis as a
measure of apoptosis (Figure 5b). The results show that
normalizing Bcl-2 protein levels reversed the apoptotic
susceptibility of p35-null podocytes and that Bcl-2 underlies
survival in podocytes.
Next, to prove that p35 indeed regulates Bcl-2 levels,
we analyzed Bcl-2 protein expression in p35-null podocytes
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Figure 3 |Cultured p35-null podocytes are more susceptible to apoptosis. Apoptosis was quantified in non-fixed cells by nuclear
Hoechst-33342 staining in wild-type (open square) and p35-null (filled square) cells under non-stressed conditions (reflected as zero in each
experiment) (a) 48 h following exposure to PAN (0–100 mg/ml), (b) 24 h after exposure to anti-glomerular antibody (0–5%, pre-immune IgG
served as control IgG), (c) 24 h after serum depletion (0–10%), (d) 24 h following TGFb1 incubation (0–10 mg/ml), and (e) 6 h after UV-C
irradiation (0–25 J/m2). Experiments were performed in triplicates and a minimum of 300 cells were counted per experiment. For statistical
analysis, analysis of variance for multiple testing was applied. *Po0.05; **Po0.01; ***Po0.001. (f) Representative photographs of Hoechst-
33342 stainings following UV-C irradiation (25 J/m2). (g) Increase in apoptosis in p35-null podocytes was confirmed by measuring cleaved
caspase-3 by Western blot analysis 6 h following UV-C irradiation (0–25 J/m2). b-Actin served as loading control.
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in which p35 expression was restored as described earlier.
p35-null podocytes transduced with human p35 showed
increase in Bcl-2 levels as compared with that in GFP-
transduced cells (Figure 5c). These results show that the
expression level of p35 influences the expression level of the
pro-survival protein Bcl-2.
Podocyte apoptosis is increased in p35 null mice with
experimental glomerulonephritis
Having shown decreased survival and increased susceptibility
to apoptosis following injury in cultured p35-null podocytes,
injury was induced in vivo. Experimental glomerulonephritis
was induced in wild-type and p35-null mice with a sheep
anti-rabbit glomeruli IgG, as previously described.16,24 This
animal model is characterized by podocyte apoptosis and
subsequent glomerular crescent formation in the absence of
any infiltrating leukocytes.
Comparable levels of sheep IgG deposition measured by
immunofluorescence staining, was observed in wild-type and
p35-null mice 7 days after injection of the anti-glomerular
antibody, which induces disease (Figure 6a–c). Podocyte
apoptosis was significantly increased in p35-null mice 3 days
after injection (wild-type 0.04±0.04 per glomerulus versus
p35-null 0.08±0.04 per glomerulus; Po0.05) as measured
by terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL) staining (Figure 6d and e). Increased
apoptosis at day 3 was subsequently accompanied by decrease
in podocyte number at day 7 (WT-1 staining, wild-type
3.03±0.55 versus p35-null 2.15±0.39; Po0.001;
Figure 6f and g). The decrease in podocyte number at day
7 correlated with increased glomerulosclerosis in p35-null
mice as compared with that in wild-type controls (R2¼ 0.55;
Figure 7a).
The clinical consequences of increased podocyte loss and
glomeruloscerosis in the absence of p35 were assessed by
measuring kidney function. Both groups developed protei-
nuria following disease induction (Figure 7b). However, the
levels of proteinuria in p35-null mice were significantly
greater at day 7 (wild-type 624.15±343.71mg/dl versus
p35-null 1,216.97±728.52mg/dl; Po0.01). Taken together
these results confirm the in vitro findings and further
emphasize the important role of p35 in podocyte survival
following injury.
DISCUSSION
Podocytes lacking p35 differentiate normally
We have previously reported that p35 binds to and activates
Cdk5 in glomerular protein lysates obtained from normal
rats.13 However, the role of p35–Cdk5 in podocyte biology
has remained elusive. In contrast to other Cdks, Cdk5 is not
directly involved in cell-cycle regulation.9 It is expressed
widely throughout the body and believed to be regulated by
the presence of specific activator proteins.25 There is a large
body of literature showing that p35/39–Cdk5 is required for
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Figure 4 |p35 is a specific regulator of podocyte apoptosis. (a) Following p35 siRNA targeting (lane 2), p35 mRNA levels were
significantly reduced as compared with control-transfected (lane 1) and non-transfected (lane 3) wild-type podocytes, (Po0.01, analysis of
variance for multiple testing). The relative concentration of p35 is shown as a ratio of p35 normalized to the housekeeping control GAPDH.
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the 2-standard curve method. (b) Following p35 siRNA targeting and UV-C irradiation (25 J/m2), caspase-3 cleavage was
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(lane 1). No caspase-3 cleavage was detected in podocytes that were not exposed to UV-C. (c) p35 expression in p35-null podocytes
was confirmed by Western blotting (lane 2). A GFP construct served as control (lane 3). b-Tubulin was included as loading control.
(d) Apoptosis (Hoechst-33342 staining) was significantly reduced in p35-null podocytes expressing human p35 as compared with
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cell maturation, differentiation, and control of apoptosis,
especially in postmitotic neurons.9 Podocytes share many
similarities with neurons, as both cell types are considered to
be terminally differentiated and highly specialized cells with
complex architectures.26
The first finding of this study was that, despite being
constitutively expressed in and restricted to podocytes in
glomeruli, p35 is not involved in glomerulogenesis or
podocyte differentiation. Moreover, mice lacking p35 have
no ultrastructural kidney defects when grown under
physiological conditions. Staining for the podocyte proteins
nephrin, synaptopodin, and podocin were similar in p35-null
and wild-type mice. Furthermore, neither podocyte number
nor renal function was affected by absence of p35. Similar
data were obtained in vitro using conditionally immortalized
p35-null cell lines. Despite the lack of p35, there was no
influence on cell proliferation or differentiation.
These data are in contrast to published data on neurons,
where lack of p35 is associated with mislocalization of
Purkinje neurons of the cerebellum.27 Moreover, Griffin
et al.13 showed in cultured podocytes inhibition of Cdk5
protein expression by siRNA or Cdk5 activity by roscovitine-
induced changes in cell morphology, with cellular elongation
and loss of process formation. Additional activators of Cdk5
might account for these effects as the substrate specificity of
Cdk5, like other Cdks, may depend in part on its particular
activating subunit. A potential candidate could be p67,
another known activator of Cdk528 that is also expressed in
podocytes (data not shown). However, the role of p67–Cdk5
in podocytes is unknown.
p35 sets a threshold for podocyte apoptosis
Podocytes function as a major barrier in the kidney to
proteinuria, and are required for normal glomerular
architecture.29 A decrease in podocyte number due to
apoptosis and/or detachment causes proteinuria and glo-
merular fibrosis, events that lead to a decline in kidney
function. Recent experimental and clinical data define the
podocyte number ‘threshold’ at which proteinuria begins and
renal function deteriorates as (i) a 0–20% decrease not
associated with proteinuria or reduced glomerular filtration
rate; (ii) a 20–40% decrease in podocyte number associated
with microalbuminuria, but normal renal function and
(iii)440% decrease in podocyte number causing proteinuria
(i.e. 4300mg/24 h) and reduced glomerular filtration rate.30
Another major finding in this study was that p35 sets the
threshold for apoptosis in podocytes following cell injury, but
not under non-stress states. Several lines of evidence support
this observation. First, there was no increase in apoptosis in
p35-null cells in the absence of cell injury. Second, similarly
there was no apoptosis in podocytes (or any other kidney
cell) in p35-null mice grown normally, without disease.
Third, following four different forms of cell injury under
culture conditions, onset of apoptosis occurred earlier in
p35-null podocytes compared to wild-type cells. Fourth, the
magnitude of apoptosis was always statistically significantly
greater in injured cultured p35-null cells as compared with
that in wild-type cells. Fifth, reducing p35 levels with siRNA
in cultured wild-type podocytes increased the onset and
magnitude of injury-induced apoptosis. Sixth, restoring p35
levels in p35-null cells by lentiviral gene transfer decreased
apoptosis, at least in part. The increased apoptosis was
independent of the triggers applied and the apoptotic
pathways involved (intrinsic versus extrinsic apoptotic path-
way or caspase-dependent versus independent).
Finally, the results of this study also showed that p35 limits
podocyte apoptosis in vivo in experimental glomerular
disease. Following injury p35-null mice showed significant
increase in podocyte apoptosis, leading to reduced podocyte
number, more severe glomerulosclerosis, and worsened
proteinuria compared with wild-type controls.
The role for p35 in neuronal survival is controversial.
Certain authors show that p35 protects neurons against
apoptosis, especially during development.9,31,32 However,
others show hyperactive p35–Cdk5 in neurogenerative
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Figure 5 |Restoring Bcl-2 protein expression rescues p35-null
podocytes from apoptosis. (a) Bcl-2 protein expression was
significantly decreased in p35-null cells (lane 2) as compared
with that in wild-type podocytes (lane 1). Retroviral infection
with (cMMP-IRES-GFP) encoding human Bcl-2 or mock (empty)
construct was confirmed by measuring GFP (lanes 3 and 4) and
protein expression of Bcl-2 in p35-null podocytes (lane 3).
Bcl-2 levels were comparable to endogenously expressed Bcl-2
levels in wild-type podocytes (lane 1). There was no effect of the
mock (empty) vector on Bcl-2 protein levels. b-Actin served as
loading control. (b) Apoptosis (caspase-3 cleavage) was markedly
decreased in p35-null podocytes stably infected with Bcl-2 (lanes
2, 4, 6, 8, 10) as compared with that in mock (empty) vector (lanes
1, 3, 5, 7, 9)-infected p35-null podocytes 6 h after UV-C irradiation
(0–25 J/m2). (c) p35 expression in p35-null podocytes (lane 1) led
to significant increase in Bcl-2 levels as compared with that in the
GFP-transduced control (lane 2). b-Actin served as loading control.
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diseases, where active p35–Cdk5 augments neuronal degen-
eration due to apoptosis. In the kidney, p35–Cdk5 levels and
activity increase during glomerular development.13 However,
we have no evidence for any pathophysiological abnormal-
ities in the kidney due to increased p35–Cdk5 activity.
p35 regulates the protein expression of Bcl-2 in podocytes
A major question is how p35 safeguards against podocyte
apoptosis? We have shown that Bcl-2 safeguards podocytes
from apoptosis.17 To test the hypothesis that decreased Bcl-2
protein levels underlie the apoptotic threshold, p35-null
podocytes were stably transduced with human Bcl-2. The
third major finding of this study was that restoring Bcl-2
protein expression in p35-null podocytes rescued these cells
from apoptosis following UV-C irradiation. In the absence of
p35, Bcl-2 protein levels were substantially reduced in
podocytes. Moreover, ecotopic expression of p35 in p35-null
cells increased Bcl-2 protein expression. Taken together, these
results indicate that p35 has pro-survival effects on
podocytes, albeit modest. These effects are mediated by
Bcl-2-dependent and Bcl-2-independent mechanisms. As
rescue of p35-null cells was incomplete, it stands to
reason that other mechanisms beyond p35 likely also
contribute to the increased apoptosis rates observed in
these cell lines. Thus, our findings are supported by recent
reports in neurons showing that p35–Cdk5 induces Bcl-2
Anti-glom Anti-glom NaC1
NS
NS
NS
P<0.05
NS
P<0.001
P<0.001
NS
P<0.001P<0.05
P<0.001
P<0.001
0.15
0.12
0.09
0.06
0.03
0.00
Day 3
+/+ p35–/–
Day 7
Day 3 Day 7
+/+ p35–/–
+/+ p35–/– +/+ p35–/–
+/+ p35–/– +/+ p35–/–
Day 3 Day 7
N
o.
 o
f T
UN
EL
 p
os
. c
el
ls
/
gl
om
er
ul
ar
 c
ro
ss
 s
ec
tio
n
2.5
2.0
1.5
1.0
0.5
0.0
7
6
5
4
3
0
1
2
N
o.
 o
f W
T-
1 
po
s.
 c
el
ls
/
gl
om
er
ul
ar
 c
ro
ss
 s
ec
tio
n
G
lo
m
er
ul
os
cle
ro
sis
 in
de
x/
 
gl
om
er
ul
ar
 c
ro
ss
 s
ec
tio
n
Sheep IgG
TUNEL
WT-1
Pas
+/+ p35–/– +/+
Figure 6 |Podocyte apoptosis is increased in p35-null mice with experimental glomerulonephritis. (a–c) There was comparable
deposition of sheep-anti-glomerular IgG as measured by immunofluorescence at day 7 following administration of anti-glomerular
antibody. (d–f) There was a significant increase in podocyte apoptosis (TUNEL staining) at day 3 of nephritis in p35-null mice (Po0.05,
analysis of variance, ANOVA). (g–i) Podocyte number (WT-1 immunostaining) was decreased in both wild-type and p35-null mice following
disease induction (day 7 Po0.001, ANOVA). However, there were significantly fewer podocytes in p35-null mice as compared with wild-type
mice (day 7 Po0.001, ANOVA). (j–l) Glomerulosclerosis index (calculated based on the percentage of glomerular tuft area affected)
increased by day 3 in mice lacking p35 as compared with wild-type mice (Po0.05, ANOVA), and was even more pronounced by day 7
(Po0.001, ANOVA). Representative images of glomeruli are shown.
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expression.31 In addition, Cheung et al.32 reported that
human Bcl-2 is a direct phosphorylation substrate of active
p35–Cdk5.
Several studies have shown a role for cell-cycle proteins in
governing podocyte apoptosis. Recently we showed that
cyclin-I, a novel activator of Cdk5, also serves to minimize
podocyte apoptosis.23 Given that both cyclin-I and p35
activate Cdk5, a model is developing, showing that activation
of Cdk5 is central to podocyte survival. By altering the levels
of the activators of Cdk5 (cyclin-I and/or p35), podocytes are
more vulnerable to injury-induced apoptosis. We speculate
that activation of Cdk5 by several proteins allows for ‘backup’
processes in order to limit apoptosis.
In conclusion, the results reported here demonstrate that
in contrast to neurons, p35 does not have a role in kidney
development (glomerulogenesis) and does not affect podo-
cyte differentiation. Rather, it sets a threshold for podocyte
survival and apoptosis in vitro and in vivo, by maintaining
Bcl-2 protein levels.
MATERIALS AND METHODS
Cell culture
Conditionally immortalized podocytes in culture were generated as
previously described from wild-type and p35 null mice (for review
see references Shankland et al.15 and Griffin et al.16). Quiescence and
differentiation were induced by culturing the cells at 37 1C for 13–15
days on Primaria plastic plates (BD Biosciences, San Jose, CA, USA)
in the absence of interferon-g.
Plasmid transfection
cMMP-IRES-GFP vectors encoding human Bcl-233 were transfected
into Phoenix Eco packaging cells (ATCC, Manassas, VA, USA) to
generate retrovirus. Retrovirus-containing media was harvested, filtered,
and applied onto subconfluent, proliferating p35-null podocytes for
infection. Infected cells were selected by fluorescence-activated cell
sorting. Infected podocytes were further subcultured, passaged, and
transferred to 37 1C to initiate growth arrest and differentiation.
Human p35 was cloned into a modified GATEWAY pENTR1A
vector followed by recombination into pLenti6.3V5/Dest (Invitrogen,
Carlsbad, CA, USA) as published previously.34
siRNA transfection
Wild-type podocytes were culture under growth-restrictive conditions.
To reduce p35 levels in wild-type cells, growth-arrested podocytes at
day 10 were transfected with 2mg of pooled siRNA-targeting p35 by
electroporation (175 volts, 200mms, 5 pulses) according to the manu-
facturer’s recommendation (Ambion, Austin, TX, USA). Non-specific
siRNA (Ambion) was included as transfection control (Table 1).
Real-time quantitative PCR
To ensure the effectiveness of siRNA, RNAwas isolated using TRIzol
reagent (Invitrogen) according to the manufacturer’s directions.
2-mg of RNA was used for cDNA synthesis using the Fermentas First
Strand cDNA Synthesis kit (Fermentas, Glen Burnie, MD, USA).
Quantitative real-time PCR was performed on a Rotor-Gene 6000
(Corbett Research, Sydney, Australia) using FAM-labeled primer
probes (Table 2; all from Applied Biosciences, Austin, TX, USA) and
the Quantace SensiMix dT reagent (Quantace, Norwood, MA, USA).
The amount of product was determined at the end of each cycle
using the Rotor-Gene software (Rotor-Gene 6000 series software
1.7). Relative gene expression was analysed with a normalizing gene
using the 2-standard curve method.
Induction and detection of apoptosis in vitro
Apoptosis was induced in 80–90% confluent, fully differentiated,
wild-type and p35-null podocytes. Each experimental condition was
applied in triplicate. Apoptosis was induced by UV-C irradiation
(0–25 J/m2), serum depletion (0–10%), or incubation with PAN
(0–100 mg/ml; Sigma-Aldrich, St Louis, MO, USA), sheep anti-rabbit
glomerular antibody (0–5%), or TGFb1 (0–10mg/ml; R&D Systems,
Minneapolis, MN, USA) and assessed by staining for nuclear
condensation in non-fixed cells with Hoechst-33342 (10mM; Sigma-
Aldrich) and by detection of caspase-3 cleavage products by Western
blot analysis.
Western blot analysis
Protein levels were measured by Western blot analysis as follows.
Cells were washed twice with cold phosphate-buffered saline (PBS)
and cells were harvested by scraping on ice. The cells were lysed in
radioimmunoprecipitation assay lysis buffer (50mM Tris–HCl (pH
8.0), 5mM EDTA, 150mM NaCl, 1% IP-40, 1% Trion X-100, 50mM
NaF, 1mM Na-orthovanadate (all from Sigma-Aldrich)) in the
presence of protease inhibitors (Roche, Indianapolis, IN, USA).
Table 1 | siRNAs
siRNA Target mRNA Strand sequence Source
4390771/s63800 p35 50-CAAGUGUUCUCUGACUUGAtt-30 Ambion
4390771/s63801 p35 50-GGACCAGGGUUUCAUCACAtt-30 Ambion
4390771/s63802 p35 50-GGUAGAGAGCUGUAAGGAAtt-30 Ambion
AM4611 Non-targeting Ambion
Abbreviation: siRNA, small interfering RNA.
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Figure 7 | Severity of glomerulonephritis is increased in
p35-null mice. (a) There was significant correlation (R2¼ 0.55)
between podocyte number (WT-1) and glomerulosclerosis for
both groups of mice (glomerulosclerosis index, periodic acid
Schiff staining). (b) Both groups developed proteinuria following
anti-glomerular antibody administration. At day 7 the amount of
proteinuria was significantly higher in p35-null mice as compared
with that in WT controls (Po0.01).
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Protein concentrations were determined by BCA protein assay
(Pierce, Rockford, IL, USA). The samples were separated on a
10% sodium dodecyl sulfate–polyacrylamide electrophoresis gel and
blotted on a polyvinylidene difluoride membrane (Sigma-Aldrich).
The membrane was incubated in 5% non-fat milk powder in TBS
(10mM Tris–HCl (pH 8.0), 150mM NaCl) solution for 3 h at room
temperature. Thereafter, the blot was incubated overnight at 4 1C
with primary antibodies (Table 3) followed by incubation with
appropriate horseradish peroxidase-conjugated secondary anti-
bodies (Sigma-Aldrich). Proteins were visualized by enhanced
chemiluminescence according to the manufacturer’s instructions
(GE Healthcare, Piscataway, NJ, USA). In some cases, membranes
were incubated in stripping buffer (100mM glycine, 1% SDS,
pH 2.5) and re-stained as stated.
Animal models
Podocyte apoptosis was studied in vivo in wild-type and p35-null
mice backcrossed onto the Balb/C background for at least
10 generations. Mice were housed according to the standardized
specific pathogen-free conditions in the University of Washington
animal facility. The Animal Care Committee of the University of
Washington, Seattle, reviewed and approved the experimental
protocol. Crescentic glomerulonephritis was induced in 8- to
12-week-old, male, wild-type and p35-null mice by intraperitoneal
injection of sheep anti-rabbit glomerular antibody (20mg/g
body weight) on two consecutive days as described previously.16,24
This model is characterized by podocyte injury, apoptosis, and
development of proteinuria and glomerulosclerosis independent of
complement activation and leukocyte infiltration of the glomeruli.
Mice were killed on days 3 and 7 after the second injection of
anti-glomerular antibody (n¼ 8–13 per strain per time point).
Urine was collected overnight from each animal before disease
induction and prior to killing for quantification of proteinuria
(sulfosalicyclin assay). Renal tissue was embedded in OCT
compound (Miles, Elkart, IN, USA) and frozen at 70 1C or fixed
in either 10% neutral buffered formalin or methyl-Carnoy’s solution
for immunostaining.
Immunostaining
Indirect immunoperoxidase staining was performed using methyl-
Carnoy’s solution- and formalin-fixed tissue from wild-type and
p35-null mice. Briefly, 4-mm tissue sections were deparaffinized in
Histo-Clear (National Diagnostics, Atlanta, GA, USA) and rehy-
drated in graded ethanol. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxidase. The sections were incubated
overnight at 4 1C with primary antibodies (Table 3) diluted in 1%
bovine serum albumin/PBS. The sections were washed repeatedly in
PBS before incubation with biotinylated mouse anti-rabbit second-
ary antibody (Jackson Immunoresearch, West Grove, PA, USA)
diluted in 1% bovine serum albumin/PBS for 1 h at room
temperature. The ABC kit (Vector Laboratories, Burlingame, CA,
USA) was used for signal amplification and 3,30-diaminobenzami-
dine (Sigma) was used as chromogen. Slides were counterstained
with methyl green (Vector Laboratories, Burlingame, CA, USA) or
hematoxylin (Sigma-Aldrich), dehydrated, and covered with Histo-
mount (National Diagnostics, Atlanta, GA, USA). Apoptosis was
measured by the TUNEL assay as described previously. Periodic acid
Schiff staining was performed for semi-quantitative assessment of
glomerulosclerosis. Frozen sections were rehydrated in PBS and
stained with fluorescein isothiocyanate-conjugated antibodies
against sheep IgG (Cappel, Durham, NC, USA) to ensure
comparable glomerular antibody deposition.
To perform immunostaining on cultured cells, podocytes in
culture were fixed by 2% paraformaldehyde, 4% sucrose followed by
0.3% Triton X-100 for permeabilization. Staining was performed by
primary antibodies diluted in PBS/bovine serum albumin (1%)
overnight at 4 1C. After three washes with PBS, appropriate
secondary antibodies, conjugated to Texas-Red (Invitrogen, Karls-
ruhe, Germany), were added for 30min at room temperature. The
coverslips were extensively washed and analyzed by fluorescence
microscopy (Leica, Deerfield, IL, USA).
Assessment of glomerulosclerosis
Glomerulosclerosis was determined using periodic acid Schiff-
stained sections for a minimum of 50 glomeruli in each animal and
Table 2 | qPCR primer probes (FAM reporter dye)
Primer probe Target mRNA Strand sequence Source
Mm99999915_g1 GAPDH TGAACGGATTTGGCCGTATTGGGCG Applied Biosystems
Mm00438148_s1 p35 ACCTTGCGCGAACCCAAAAGATGCA Applied Biosystems
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; siRNA, small interfering RNA.
Table 3 | Primary antibodies
Target protein Antibody Dilution (WB) Dilution (IHC/IF) Source
b-Actin ab6276 1:100,000 — Abcam
Bcl-2 CST-2876 1:1000 — Cell Signaling
Cleaved caspase-3 CST-9664 1:1000 — Cell Signaling
GFP CST-2555 1:1000 — Cell Signaling
Nephrin RDI-PROGN2 — 1:1500/1:100 Fitzgerald
Podocin Ab50339 — 1:4000 Abcam
Synaptopodin RDI-PRO65194 — 1:20/1:1 Fitzgerald
b-Tubulin sc-9104 1:200 — Santa Cruz
V5 tag MCA1360 1:5000 — Serotec
WT-1 sc-192 — 1:2000/1:100 Santa Cruz
Abbreviations: GFP, green fluorescent protein; IF, immunofluorescence; IHC, immunohistochemistry; WB, Western blotting.
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was graded quantitatively based on the percentage of glomerular tuft
area involvement as follows: grade-1, o25%; grade-2, o25–50%;
grade-3, o50–75%; and grade-4, o75–100%.
Statistical analysis
All results are expressed as mean±s.d. Statistical significance was
evaluated using GraphPad Prism version 4.00c for Macintosh
(GraphPad Software, San Diego, CA, USA). Analysis of variance
(ANOVA) with Tukey–Kramer adjustment for multiple comparisons
was applied. A P-value o0.05 was considered significant.
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